

Therapeutic vaccination with auto-antigen mRNA loaded Tol-cLNP cures murine model of multiple sclerosis

Dr Paulien Baeten

Prof. Dr Bieke Broux

Dr Stefaan De Koker

BIOMED




BIOMEDISCH
ONDERZOEKSINSTITUUT



UHASSELT

ethernä

Multiple sclerosis – Goal – Results – Conclusion



Need for a new therapy

Multiple sclerosis – Goal – Results – Conclusion


Re-establish tolerance in an antigen-specific manner



1. Antigen-specific,
immune-silent mRNA



2. Tolerizing customized
lipid nanoparticles (Tol-cLNP)



Multiple sclerosis – Goal – Results – Conclusion

Re-establish tolerance in an antigen-specific manner




1. Antigen-specific,
immune-silent mRNA



Reduced activation of
interferon regulatory pathway



2. Tolerizing customized
lipid nanoparticles (Tol-cLNP)



Targets APCs in
liver and spleen




Multiple sclerosis – Goal – Results – Conclusion

EAE





Multiple sclerosis – Goal – Results – Conclusion

Prophylactic potential



Multiple sclerosis – Goal – Results – Conclusion

Therapeutic potential



Multiple sclerosis – Goal – Results – Conclusion

- Tolerizing capacity of mRNA and Tol-cLNP
- Therapeutic efficacy *in vivo*
 - Prevents disease development
 - Prevent infiltration inflammatory CD4 T cells
 - Cures disease
 - Outperforms MS approved drug

Acknowledgements

Bieke Broux
Tessa Schalley
Niels Hellings
An voets

CBN team

UMSC | Universitair
MS Centrum



Stefaan de Koker
Florence Lambolez
Karen Beets
Jana De Vrieze
Bart Vanderborght
Jurgen Van den Heuvel
Isma Varela
Elise Seynaeve
Sinem Demirel Asci
Sabah Kasmi
Senne Dillen
Ruben De Coen

BIOMED
BIOMEDISCH
ONDERZOEKSINSTITUUT

►► **UHASSELT**

U3iLim
University Biobank Limburg

ethernä